Schering plant fire spares contrast unit

Article

A fire this month at one of Schering's plants in Bergkamen, Germany,had no effect on the pharmaceutical company's contrast agent manufacturing,according to a Schering spokesperson. The fire broke out July16 at Plant B, which manufactures hormone

A fire this month at one of Schering's plants in Bergkamen, Germany,had no effect on the pharmaceutical company's contrast agent manufacturing,according to a Schering spokesperson. The fire broke out July16 at Plant B, which manufactures hormone products, and causedestimated damage of over DM 1 million ($674,000) before it wasextinguished. Schering's contrast manufacturing facility, PlantF, is in a separate building from the one in which the fire brokeout, according to the spokesperson.

In other Schering news, the company is expected to post strongerrevenues and income this year, according to Reuter SecuritiesReport. An analyst said the improvement is due to added revenuesfrom several acquisitions made last year, including that of contrastinjector firm Medrad. An improved exchange rate and the end ofextraordinary charges related to its withdrawal of Isovist 280from the market will also help Schering's bottom line. The analystestimated that Schering will report revenues for the year of DM5.7 billion ($3.83 billion), up 24%, and income of DM 337 million($227 million), up 35%.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.